Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases

Nuclear Medicine Communications

Volumn 31, Issue 11, 2010, Pages 938-944

  Wiering, Bastiaan ^a   Adang, Eddy M M ^a   Van Der Sijp, Joost R M ^b   Roumen, Rudi M ^e   De Jong, Koert P ^f   Comans, Emile F I ^c   Pruim, Jan ^g   Dekker, Helena M ^a   Ruers, Theo J M ^d   Krabbe, Paul F M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Departments of Surgical Oncology   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e MÁXIMA MEDICAL CENTER   (Netherlands)

^f Departments of Hepato Pancreato Biliary Surgery and Liver Transplantation   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

F 18 fluorodeoxyglucose positron emission tomography; colorectal cancer; cost utility analysis; metastases

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SCINTISCANNING; CANCER SURGERY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LAPAROTOMY; LENGTH OF STAY; LIVER METASTASIS; LIVER SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COSTS AND COST ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 77957995895     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833fa9ba     Document Type: Article

References (31)

1. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27-32.
2. Russell AH, Tong D, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, Luk KH. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983; 9:361-365. (Pubitemid 13055181)
3. Gibbs JF, Weber TK, Rodriguez-Bigas MA, Driscoll DL, Petrelli NJ. Intraoperative determinants of unresectability for patients with colorectal hepatic metastases. Cancer 1998; 82:1244-1249.
4. Mann CD, Neal CP, Metcalfe MS, Pattenden CJ, Dennison AR, Berry DP. Clinical Risk Score predicts yield of staging laparoscopy in patients with colorectal liver metastases. Br J Surg 2007; 94:855-859.
5. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991; 9:1105-1112.
6. Wiering B, Krabbe PF, Dekker HM, OyenWJ, Ruers TJ. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 2007; 14:771-779.
7. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243-254.
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
9. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:818-825.
10. Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of patterns of recurrence. Surgery 1986; 100:278-284.
11. Ruers TJ, Joosten JJ, Wiering B, Langenhoff BS, Dekker HM, Wobbes T, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007; 14:1161-1169.
12. Topal B, Kaufman L, Aerts R, Penninckx F. Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 2003; 29:248-253.
13. Bipat S, Van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology 2005; 237:123-131.
14. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224:748-756.
15. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20:4453-4458.
16. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
17. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 2006; 141:1220-1226.
18. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluoro-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104:2658-2670.
19. Lejeune C, Bismuth MJ, Conroy T, Zanni C, Bey P, Bedenne L, et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005; 46:2020-2028.
20. Park KC, Schwimmer J, Shepherd JE, Phelps ME, Czernin JR, Schiepers C, Gambhir SS. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001; 233:310-319.
21. Zubeldia JM, Bednarczyk EM, Baker JG, Nabi HA. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases. Cancer Biother Radiopharm 2005; 20:450-456.
22. Beard SM, Holmes M, Price C, Majeed AW. Hepatic resection for colorectal liver metastases: a cost-effectiveness analysis. Ann Surg 2000; 232:763-776.
23. Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, et al. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg 2003; 237:544-555.
24. Ruers TJ,Wiering B, Van DS Jr, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med 2009; 50:1036-1041.
25. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
26. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004; 13:1247-1253.
27. Langenhoff BS, Krabbe PF, Wobbes T, Ruers TJ. Quality of life as an outcome measure in surgical oncology. Br J Surg 2001; 88: 643-652.
28. Oostenbrink JB, Koopmanschap MA, Rutten FF. Manual for cost research; methods and directive prices for economic evaluations in health care, Dutch manual appeared in 2000. Published by the Dutch Government.
29. Raad voor de Volksgezondheid (RvZ). Sensible and sustainable care, Dutch communique from the health department. RvZ; Zoetermeer: 2006.
30. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979; 7:1.
31. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007-1016.